A recently unsealed suit accuses the Indianapolis-based drugmaker of offering free nursing services to doctors to induce them to prescribe the company’s products.
In Indiana, Alex Azar was an influential member of a public airport board, tasked with oversight of human resources matters, when he defended the conduct of the airport CEO who was under fire for spending public money on travel, golf fees, steak dinners and Super Bowl tickets.
Taltz, launched in 2016 to treat plaque psoriasis, won approval from the Food and Drug Administration for a second indication—treating adults with a form of arthritis.
The 5-year-old Carmel biotech has won plenty of attention from Wall Street and has secured more than $100 million through licensing deals and a stock offering to help fund expensive clinical trials.
Eli Lilly and Co. announced this fall it was reviewing whether to sell or spin off the division, which employs 6,500 people, including 800 at its Greenfield headquarters.
The university’s $205 million in big gifts was about two-thirds of the $302.9 million in gifts of $1 million or more given by individuals to Indiana not-for-profits in 2017.
Pfizer said it will continue its support of potential blockbuster drug tanezumab, a late-stage pain treatment in development with Indianapolis-based Eli Lilly and Co.
Eli Lilly and Co. CEO Dave Ricks said Monday that the recent changes in U.S. tax policy will help the drugmaker lower its global tax burden as he continues to look for deals in areas like oncology.
Former Eli Lilly exec Alex Azar, who is President Donald Trump’s pick to lead the Department of Health and Human Services, faces senators at his second hearing on Capitol Hill on Tuesday.
Alex Azar, a former Eli Lilly and Co. executive, acknowledged to the Senate Finance Committee that drug prices are too high and said he'd work to lower them if confirmed as secretary of Health and Human Services.
A slimmed-down Eli Lilly and Co., thousands of employees lighter after its biggest restructuring in nearly a decade, is now looking high and low for deals to bulk up its drug pipeline.
North American companies, which fell out of favor among acquirers last year, are back on the shopping list in 2018, making up almost 60 percent of all announced transactions in 2018.
More deals could be on the horizon as dozens of companies—including local powerhouses such as Simon, Eli Lilly and Anthem—game out what Amazon’s huge ambitions could mean for their bottom lines.
Corporate America, including some of Indiana’s top executives, implored Congress to give it a tax cut—a move businesses said would translate into more U.S. jobs and investment. Now that’s occurred.
President Donald Trump's second health secretary won Senate approval Wednesday, clearing the way for former Eli Lilly and Co. executive Alex Azar to take over a sprawling department shaken by his predecessor's early exit.
